Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed … – GlobeNewswire (press release)
Pharmaceuticals News |
Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR–T Stem Cell Memory Product in Patients with Relapsed …
GlobeNewswire (press release) SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced initial data from the lowest dose cohort of … B-cell Maturation Antigen (BCMA) Targeted Therapies Market Headed for Growth and Global Expansion by 2020 |
